Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.8% – Still a Buy?

Posted by Brian Himes on May 11th, 2026

Eli Lilly and Company logo Eli Lilly and Company (NYSE:LLY – Get Free Report) traded up 1.8% during mid-day trading on Monday . The stock traded as high as $995.00 and last traded at $965.8490. 3,102,072 shares traded hands during mid-day trading, a decline of 3% from the average session volume of 3,212,879 shares. The stock had previously closed at $948.45.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Barclays raised its price target on Eli Lilly to $1,400 from $1,350 and kept an Overweight rating, signaling continued confidence in the company’s long-term growth outlook. Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY)
Positive Sentiment: Investor sentiment is also being lifted by reports that Lilly’s revenue growth remains exceptionally strong, with the company’s CFO discussing a 56% year-over-year revenue beat. Eli Lilly CFO Lucas Montrace Explains What Drove 56% Year-over-Year Revenue Beat
Positive Sentiment: Lilly’s obesity and diabetes franchise continues to be viewed favorably, with commentary noting that Mounjaro has overtaken Merck’s Keytruda as the best-selling drug, reinforcing the strength of its GLP-1 portfolio. Eli Lilly’s Mounjaro surpasses Merck’s Keytruda as best-selling drug
Neutral Sentiment: Several market articles highlighted Lilly as a top momentum and growth stock, adding to the bullish narrative but offering little new company-specific information. Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
Neutral Sentiment: Lilly was also mentioned in a proposed acquisition of Centessa Pharmaceuticals, which could be mildly strategic over time but is not yet a direct earnings driver. Centessa Pharmaceuticals Investor Alert
Negative Sentiment: Eli Lilly paused an obesity awareness campaign in India after the country’s drugs regulator warned it may violate rules against indirect prescription-drug advertising, creating a near-term regulatory overhang. Exclusive: Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, May 1st. Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, May 4th. Wolfe Research restated an “outperform” rating and set a $1,325.00 price objective on shares of Eli Lilly and Company in a research report on Monday, May 4th. Finally, UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1,218.33.

Get Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Trading Up 1.8%

The company has a market cap of $909.58 billion, a P/E ratio of 34.31, a P/E/G ratio of 1.03 and a beta of 0.48. The stock’s 50-day moving average is $943.90 and its two-hundred day moving average is $990.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period last year, the firm earned $3.34 earnings per share. The company’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. bought a new position in Eli Lilly and Company in the fourth quarter worth approximately $25,000. Osbon Capital Management LLC bought a new position in Eli Lilly and Company in the fourth quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC raised its position in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares during the period. Basso Capital Management L.P. bought a new position in Eli Lilly and Company in the fourth quarter worth approximately $30,000. Finally, 10Elms LLP raised its position in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares during the period. 82.53% of the stock is currently owned by institutional investors.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.